89bio, Inc. (ETNB)
NASDAQ: ETNB · Real-Time Price · USD
8.88
-0.35 (-3.79%)
At close: Mar 3, 2025, 4:00 PM
8.98
+0.10 (1.13%)
After-hours: Mar 3, 2025, 6:58 PM EST
89bio Employees
89bio had 70 employees as of December 31, 2023. The number of employees increased by 25 or 55.56% compared to the previous year.
Employees
70
Change (1Y)
25
Growth (1Y)
55.56%
Revenue / Employee
n/a
Profits / Employee
-$5,243,986
Market Cap
1.30B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 70 | 25 | 55.56% |
| Dec 31, 2022 | 45 | 4 | 9.76% |
| Dec 31, 2021 | 41 | 14 | 51.85% |
| Dec 31, 2020 | 27 | 7 | 35.00% |
| Dec 31, 2019 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
ETNB News
- 4 days ago - 89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates - GlobeNewsWire
- 25 days ago - 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - 89bio's Pegozafermin Is Now Gaining Momentum - Seeking Alpha
- 4 weeks ago - 89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 5 weeks ago - 89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 7 weeks ago - 89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward - Seeking Alpha
- 3 months ago - 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024 - GlobeNewsWire
- 3 months ago - 89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire